Tissue and Specimen Core

组织和样本核心

基本信息

项目摘要

The Specimen Core provides part of the infrastructure support for Projects 1 - 5 as well as for future pilot and developmental projects. It has been designed to meet the needs of these projects plus serve as a stand- alone resource for collaborative efforts with other SPOREs. This Core will provide a well-organized and standardized system of specimen collection, storage, distribution and related clinical/research information dissemination that is based on over two decades of experience. There will be consistency and quality assurance in the pathological analysis of tissue specimens. Furthermore, the centralized management of the specimens will facilitate their distribution based upon the priorities defined by a panel of investigators familiar with all of our SPORE research endeavors. The operations of this Core group into 5 components: 1. Specimen acquisition, processing, quality control, storage and accessioning into databases. 2. A development program to continually improve the quality and efficiency with which we obtain tissue samples and derivative products. 3. A prostate cancer xenograft maintenance, development and study program. 4. Laboratory services, including interpretation of tissues and tissue localization studies by a urologic pathologist, immunohistochemistry (IHC), quantitative RT-PCR, and immunoassays, i.e. PSA, and tissue culture. The Core will also perform pre-clinical studies using our xenograft resources, and 5. An administrative program to obtain samples from minority patients, prioritize the distribution of specimens, conduct a quality control program, ensure patient confidentiality and compliance with IRB requirements, and to interact with other prostate SPOREs. The performance of translational research mandates that investigators have ready access to well documented clinical specimens and relevant biological models. The investigators directing the Biospecimen Core have decades of experience in recognizing these needs and providing such services not only to local investigators but to those who request specimens on a world-wide basis. For example, samples of specimens from our rapid autopsy program (e.g. prostate cancer bone metastases) and our LuCaP series of prostate cancer xenografts have been distributed internationally. In this renewal, such interactions with our own SPORE investigators, those collaborations with other SPORE investigators and collaborations with non- SPORE investigators will be a high priority. This will truly enhance the translational aspects of the NW Prostate Cancer SPORE.
标本核心提供了针对项目1-5的基础设施支持以及未来的飞行员和 发展项目。它旨在满足这些项目的需求,并作为独立 仅与其他孢子进行协作的资源。该核心将提供一个井井有条的 标本收集,存储,分布和相关临床/研究信息的标准化系统 基于超过二十年的经验的传播。会有一致性和质量 在组织标本的病理分析中保证。此外,集中管理 标本将根据研究人员的定义的优先级来促进其分布 熟悉我们所有的孢子研究工作。该核心组的操作分为5个组成部分: 1。采集,处理,质量控制,存储和登录到数据库中。 2。开发计划,以不断提高我们获得组织的质量和效率 样品和衍生产品。 3。前列腺癌异种移植,发展和研究计划。 4。实验室服务,包括通过泌尿科对组织和组织定位研究的解释 病理学家,免疫组织化学(IHC),定量RT-PCR和免疫测定,即PSA和 组织培养。核心还将使用我们的异种移植资源进行临床前研究,并 5。一项行政计划,以获取少数族裔患者的样本,优先分配 标本,进行质量控制计划,确保患者机密性和遵守IRB 要求,并与其他前列腺孢子互动。 翻译研究的表现要求调查人员可以准备好井井有条 记录了临床标本和相关的生物学模型。指导生物循环的调查人员 核心在识别这些需求并提供此类服务不仅为本地提供了数十年的经验 调查人员,但对那些在世界范围内要求标本的人。例如,样本 我们快速尸检计划(例如前列腺癌骨转移)和Lucap系列的标本 前列腺癌异种移植物已在国际上分布。在这种续约中,这种与我们的互动 自己的孢子调查员,与其他孢子调查员的合作以及与非孢子的合作 孢子调查人员将是一个很高的优先事项。这将真正增强西北的翻译方面 前列腺癌孢子。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ROBERT Louis VESSELLA其他文献

ROBERT Louis VESSELLA的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ROBERT Louis VESSELLA', 18)}}的其他基金

Facility Biospecimen and Xenograft Core
设施生物样本和异种移植核心
  • 批准号:
    8475915
  • 财政年份:
    2013
  • 资助金额:
    $ 31.22万
  • 项目类别:
Profiling and Characterizing Prostate Cancer Tumor Dormancy in the Bone Marrow
骨髓中前列腺癌肿瘤休眠的分析和特征
  • 批准号:
    7943979
  • 财政年份:
    2009
  • 资助金额:
    $ 31.22万
  • 项目类别:
Profiling and Characterizing Prostate Cancer Tumor Dormancy in the Bone Marrow
骨髓中前列腺癌肿瘤休眠的分析和特征
  • 批准号:
    7809196
  • 财政年份:
    2009
  • 资助金额:
    $ 31.22万
  • 项目类别:
Tissue and Pathology Core
组织和病理学核心
  • 批准号:
    7244285
  • 财政年份:
    2006
  • 资助金额:
    $ 31.22万
  • 项目类别:
Biospeciman Core
生物样本核心
  • 批准号:
    8120392
  • 财政年份:
    2002
  • 资助金额:
    $ 31.22万
  • 项目类别:
Transmembrane Proteases and Prostate Carcinogenesis
跨膜蛋白酶和前列腺癌发生
  • 批准号:
    8303430
  • 财政年份:
    2002
  • 资助金额:
    $ 31.22万
  • 项目类别:
The Detection, Isolation and Characterization of Disseminated Tumor Cells
播散性肿瘤细胞的检测、分离和表征
  • 批准号:
    8303429
  • 财政年份:
    2002
  • 资助金额:
    $ 31.22万
  • 项目类别:
Mechanisms and Markers of Prostate Cancer Metastases
前列腺癌转移的机制和标志物
  • 批准号:
    8120394
  • 财政年份:
    2002
  • 资助金额:
    $ 31.22万
  • 项目类别:
Mechanisms and Markers of Prostate Cancer Metastases
前列腺癌转移的机制和标志物
  • 批准号:
    8303434
  • 财政年份:
    2002
  • 资助金额:
    $ 31.22万
  • 项目类别:
Transmembrane Proteases and Prostate Carcinogenesis
跨膜蛋白酶和前列腺癌发生
  • 批准号:
    8518248
  • 财政年份:
    2002
  • 资助金额:
    $ 31.22万
  • 项目类别:

相似海外基金

COLLABORATIVE PERINATAL PROJECT IN OBESITY GENOME-WIDE ASSOCIATION STUDIES
肥胖全基因组关联研究围产期合作项目
  • 批准号:
    10670539
  • 财政年份:
    2022
  • 资助金额:
    $ 31.22万
  • 项目类别:
Core 1: Sample Procurement and Clinical Core
核心1:样品采购和临床核心
  • 批准号:
    10222318
  • 财政年份:
    2020
  • 资助金额:
    $ 31.22万
  • 项目类别:
Clinical Core
临床核心
  • 批准号:
    10622636
  • 财政年份:
    2020
  • 资助金额:
    $ 31.22万
  • 项目类别:
Core 1: Sample Procurement and Clinical Core
核心1:样品采购和临床核心
  • 批准号:
    10680629
  • 财政年份:
    2020
  • 资助金额:
    $ 31.22万
  • 项目类别:
Clinical Core
临床核心
  • 批准号:
    10164695
  • 财政年份:
    2020
  • 资助金额:
    $ 31.22万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了